Special Issue

Advances in Antifungal Development: Discovery of New Drugs and Drug Repurposing

Message from the Guest Editors

Current antifungal interventions have often exhibited limited efficacy in treating fungal infections, partly because the development of new antifungal drugs has become stagnant. Only three classes of antifungal drugs are used in clinical settings, namely, azoles, polyenes. and echinocandins; azoles and polyenes were introduced in 1980, while the echinocandin caspofungin was approved for the clinical uses after 2000. Meanwhile, an alternative drug discovery strategy termed drug repurposing has been explored recently. Antifungal drug repurposing is the repositioning process of already marketed pharmaceutical drugs previously approved for curing human diseases such as cardiovascular diseases, arthritis, atherosclerosis, etc., to control fungal infections. One of the advantages of drug repurposing is that the mechanisms of action or safety of the drugs have been well-characterized. This Special Issue will discuss recent advances in the field of antifungal drug discovery or repurposing with hopes of enhancing the efficiency of current antifungal interventions and identifying new antifungal drugs or alternatives.

Guest Editors

Dr. Jong Heon Kim

Dr. Luisa W. Cheng

Dr. Kirkwood Land

Deadline for manuscript submissions

closed (19 November 2021)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/56338

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

